Showing results (131-140 of 244) with videos related to
Sort By:
Pageof 25
Hepatology Communications|March 8, 2021
Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of CurePhilip R Spradling, Yuna Zhong, Anne C Moorman, et al.Population Health Management|August 14, 2023
The Predictive Value of International Classification of Disease Codes for Chronic Hepatitis C Virus Infection Surveillance: The Utility and Limitations of Electronic Health RecordsWinston E Abara, Anne C Moorman, Yuna Zhong, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 11, 2022
Lower Rates of Emergency Department Visits and Hospitalizations Among Patients With Chronic Hepatitis C With Sustained Virological Response to Interferon-Free Direct-Acting Antiviral Therapy (2014-2018)Stuart C Gordon, Eyasu H Teshale, Philip R Spradling, et al.The Journal of Infectious Diseases|January 18, 2022
Incidence of Malignancies Among Patients With Chronic Hepatitis B in US Health Care Organizations, 2006-2018Philip R Spradling, Jian Xing, Yuna Zhong, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 4, 2014
Trends in HCV RNA testing among HCV antibody-positive persons in care, 2003-2010Philip R Spradling, Xin Tong, Loralee B Rupp, et al.Hepatology (Baltimore, Md.)|February 1, 2013
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral loadStuart C Gordon, Zahary Krastev, Andrzej Horban, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 22, 2014
Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter studyNezam H Afdhal, Bruce R Bacon, Keyur Patel, et al.Alimentary Pharmacology & Therapeutics|February 18, 2022
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current dataYoung-Suk Lim, Wai-Kay Seto, Masayuki Kurosaki, et al.Antiviral Therapy|October 11, 2012
A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patientsEric J Lawitz, John M Hill, Thomas Marbury, et al.Journal of Clinical Gastroenterology|April 7, 2020
Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017Philip R Spradling, Jian Xing, Loralee B Rupp, et al.Pageof 25